Charles Alsdorf, Director, Capital Efficiency Services, Deloitte
Charles is Director in Deloitte Financial Advisory Services LLP, with over 21 years of experience in valuation, strategy, decision analysis and corporate finance. He focuses his practice on evaluating strategic investment decisions in times of volatility and change. He leads Deloitte FAS’ practice in capital efficiency, which deploys leading strategy and quantitative methodologies to help companies make optimal decisions in the face of a portfolio of many competing capital funding requests. His experience includes applying multi-attribute decisions analysis to complex portfolio investment challenges, as well as applying decision analysis and real options analysis to major capital projects and transactions. He also co-leads Deloitte FAS’ practice in portfolio valuation services for the alternative investment industry including hedge funds and private equity funds. And he is one of the service offering leaders in Deloitte’s Enterprise Sustainability program. He has also been selected to participate in Deloitte’s Eminence Fellowship program based on his work in capital efficiency. He also serves as a leader in Deloitte's Diversity & Inclusion program. Prior to joining Deloitte FAS, he served as vice president of technology strategy for Standard & Poor's global bond rating agency, and before that as director of valuation for PricewaterhouseCoopers.
John Ansell, Senior Partner, Commercial, TranScrip Partners
John Ansell has been an independent pharma industry consultant based in the UK since 1989. Since 2012 he has also been a Senior Partner at TranScrip Partners, a global specialty contract organisation that supports pharma product development and life cycle management. He concentrates on international projects with a commercial and strategic emphasis, reflecting his previous 20 years in the industry in marketing and business development. John advises companies of all sizes including start-ups, as well as those providing services to the industry or investing in it: some 150 clients in all. A Biochemistry graduate with a Masters degree in Business Studies, John Ansell started his career in the industry in Holland with Organon. He subsequently worked for Schering AG and Fisons in the UK, and again in Holland, with Solvay. Lastly, from 1985 to 1989 he worked in international marketing for Glaxo Holdings. Since 2007 he has been an Honorary Consultant to the University of Manchester School of Pharmacy and Pharmaceutical Sciences. John is a frequent speaker and chair at industry conferences. He is also the author of over 50 articles on pharmaceutical issues. His book "Transforming Big Pharma – Considering the Strategic Alternatives" was published by Gower Publishing in 2013 (see www.johnansell.com).
Sultan Aziz, Senior Director, Capacity Management, Janssen Pharmaceuticals
Sultan is responsible for providing overall leadership and direction to the Capacity Management department within the PMO. His responsibilities include capacity and demand analyses, operational risk analysis and scenario modeling in support of the Janssen R&D Book-of-Work development pipeline and associated business processes.
Sultan joined JnJ from Merck & Co., where he held key positions of increasing responsibility in R&D Business Operations, Project Management, R&D and Manufacturing Finance. His broad background includes basic research drug discovery and development, launch of several successful products, licensing and acquisitions as well as Over-the-Counter Rx to OTC switches. Sultan holds a MBS in Finance and BA in Biology.
Greg Bayer, Group Director, R&D Scheduling & Resource Management, Bristol-Myers Squibb
Greg Bayer leads the R&D Scheduling and Resource Management function in R&D Operations, which is responsible for drug project scheduling, resource & capacity planning and enabling pipeline planning and operations in various settings, including the R&D budget process, the study start approval process, GDOC operations, and others. Prior to his current role, Greg was Director of Global Business Operations in Global Medical, in which he led the annual medical planning process. He joined BMS from the Health & Life Sciences strategy practice at Accenture, where he worked with pharmaceutical industry clients in the areas of R&D governance, resource management, brand strategy, sales acceleration and shareholder value creation. Prior to business school, he worked in a molecular biology research position and as a project manager at a CRO. Greg holds a Bachelors degree in Biology from Wake Forest University and an MBA from the Kenan-Flagler Business School at UNC-Chapel Hill.
Richard Bayney, Ph.D., President & Founder, Project & Portfolio Value Creation
Dr. Richard Bayney is President & Founder of Project & Portfolio Value Creation, a consulting boutique providing training and education in project, program, portfolio, resource, and risk management as well as client services in strategic, business, and portfolio planning. He is an adjunct faculty member at the University of Pennsylvania. Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. He obtained his M.Sc. and Ph.D. from University of London, MBA from Columbia University, and PMP from the Project Management Institute.
Pasquale Cetera, Ph.D., Consultant, MKTG Pharmaceuticals
Pasquale Cetera is a Senior Consultant for the Drug Industry with 33 years of experience in many roles, in Strategic Planning, R&D and Commercial. He was recently responsible for Portfolio Management & Strategy in GHH at Merck; in this position for 6 years, he worked closely with MRL (Merck Research Laboratories) to ensure continuous alignment between commercial and R&D. Before joining Merck, Pasquale was the Head of a Global Franchise in Novartis for three years. Previously, he covered several positions in Marketing and in R&D in Pharmacia/Pfizer. He has been managing the pre-launch and launch activities on many products (Celebrex, Detrol, Enablex, Reclast, Zelnorm, Caverject, Mycobutin, Idamycin, etc.). Pasquale is Italian, although he has worked in the US since 1989; he holds a Ph.D. in Chemistry from Pisa University and an MBA from Bocconi University.
Jennifer Daubenspeck, Ph.D., Manager, Reporting and Capabilities, Bristol-Myers Squibb
Jennifer Daubenspeck has been at BMS for 8 years and currently supports two Planisware systems: ePlan, the scheduling and resource forecasting system for R&D, and eTime, the time tracking system. She leads the Business Working Group for eTime, and supports 200 coordinators and more than 6000 users. In ePlan, Jennifer has worked with resource management and functional areas to develop and maintain resource forecasting algorithms for roles on pharmaceutical development teams and clinical teams. Prior to BMS, Jennifer was an assistant professor at the University of San Diego. Jennifer holds a PhD in Industrial Engineering from Lehigh University, and a bachelor’s in Mathematics from Penn State.
Jeffrey Davis, M.D., Director, Human Health and Performance (HH&P), CMO, NASA Johnson Space Center
Jeffrey R. Davis, M.D., MS currently serves as Director, Human Health and Performance (HH&P) and as the Chief Medical Officer for the NASA Johnson Space Center. The HH&P Directorate provides the research and technology development required for exploration as well as all human health and performance support to space flight operations of the International Space Station. Dr. Davis serves as the Director, NASA Human Health and Performance Center (NHHPC), a collaborative organization of over 135 members across government, industry, academia and non-profit organizations; and Deputy Director of the Center of Excellence for Collaborative Innovation (CoECI), a collaborative center to promote the use of prizes within the federal government. Dr. Davis received his B.S. degree in Biology from Stanford University and M.D. degree from the University of California at San Diego. He also holds a Master of Science (MPH equivalent) degree from Wright State University. His residency training included internal medicine and aerospace medicine, and he is certified by the American Board of Preventive Medicine.
Carmel Egan, Ph.D., Vice President, Project Management, Eli Lilly & Co.
J. Carmel Egan, Ph.D., was named vice president of project management for Lilly in March 2005. Prior to that, she had been vice president, manufacturing science and technology since 2001. She had been executive director of product development since July 2000. She is a member of the senior management council. Born in Ireland, she received a Bachelor of Science degree in chemistry from University College, Cork, in 1980 and a doctorate in chemistry in 1984 from the University College, Dublin. She joined Lilly in 1986 at the affiliate in Kinsale, Ireland, following an industrial postdoctoral fellowship in Puerto Rico. In 1990, she transferred to the United States at Clinton Laboratories as group leader of technical services. Egan moved to corporate headquarters in Indianapolis as manager of development projects management in 1992. She was named head of chemical process research in 1995 and the next year was named manager of regulatory affairs: chemistry, manufacturing and control. She was named director, development projects management in 1997. The next year, she became the program team leader for SERM III, and the following year was named product team leader for SERM III. In July 2000, she was named executive director of product development. She was a recipient of the 1999/2000 Chairman's Ovation Award. Sponsored by Sidney Taurel, chairman and chief executive officer, the award is presented annually to a select number of leaders who demonstrate an exceptional ability to motivate and develop people.
Philip Fahringer, Analyst, Center for Innovation, Lockheed Martin
Philip A. Fahringer is an Operations Analyst with over 27 years of combined experience in the military and industry. He has focused his analysis on developing strategic decision support applications. These applications enable decision makers to factor in uncertainty around their assumptions and then make analytically based decisions regarding which courses of action will yield the best resultsin their judgment under the widest range of likely scenarios. The results are presented in terms of overall performance expectations, overall costs, performance risk and budget risk. Currently, he is the lead developer for the Dynamic Comparative Analysis Methodology for Lockheed Martin.
Jonathan Freeman, Ph.D., Senior Vice President, Head of Portfolio Management, Merck Serono
Jonathan is since 2012 SVP Head of Global Portfolio Management, Global Business Development & Strategy; previously he was Head of Licensing, Global Business Development. Before Rejoining Merck Serono in 2008 Jonathan was Director, Licensing and M&A (Europe/ECEMEA)at Baxter Healthcare from 2006. In 2000 he started at Serono as Director, Licensing & Strategy. He is a graduate from the University of Cambridge(UK) and has a Ph.D from the University of Edinburgh (UK).
Krish Ghosh, Ph.D., Vice President, Informatics, Covance
Krish Ghosh is Vice President of Informatics at Covance, and serves as a member of the Informatics Executive Management team reporting to the CDO of the company. Prior to this, Krish was the Vice President of Global Resource Management and reported to the CFO. Krish joined Covance in May of 2006. He is responsible for leading Global Informatics activities. He has developed innovative methods and solutions to help drive value in the drug development continuum, business performance/expansions, and supported the growth, capacity management, expansion efforts, and profitability of the company. In addition, Krish has 13 years of Pharmaceutical industry experience and 4 years in academics. He was the Director of Project Planning and Information at Wyeth and held different positions in R&D at BMS. Krish holds a Ph.D. in Statistics and an MBA in Finance from Temple University.
Arkady Gusev, Ph.D., US Operations Head, Biomarker Development (BMD), Translational Medicine, Novartis Institutes for BioMedical Research, Inc.
Dr. Arkady Gusev is currently a head of US Operations in Biomarker Development, Translational Medicine of Novartis Institute of Biomedical Research. From 2002 to 2009 Arkady Gusev led the Business and Technology Operations unit in the Department of Pharmacokinetics, Dynamics and Metabolism in Pfizer Global Research Division. Arkady Gusev research interests include analytical instrumentation, project and portfolio management, clinical biomarker development and utilization, clinical outsourcing, operational excellence and regulatory compliances.
Ling He, Ph.D., Director, Clinical Bioanalysis, Clinical Pharmacology and Translational Medicine, Daiichi Sankyo Pharma Development
Ling He is currently the head of Clinical Bioanalysis Daiichi Sankyo Pharma Development. His function supports regional and global clinical development programs from phase 1 to 3. Since joining pharma industry in 1997, Ling has worked in multiple organizations (Schering Plough, QPS and Daiichi Sankyo) and at different stages of drug R&D (discovery, preclinical and clinical), and supported multiple drug filings. As a scientist his research interests/expertise includes regulated bioanalysis, drug metabolism and clinical pharmacology. Ling received his Ph.D. degree in Analytical Chemistry at University of Michigan.
Hartmut Hein, Ph.D., Director, Global Planning Office, Merck KGaA
Hartmut has more than 10 years experience in project management. After receiving his Ph.D. in Chemistry he started in 1999 in process development. Over the years he held various positions with increasing responsibility as CMC-Leader, in Manufacturing and Clinical R&D. With the merger of Merck KGaA and Serono S.A. he was part of a team setting up Project Management for Merck Serono heading the PMO function. With the reorganization of Merck Serono initiated in 2012 he took over the Global Planning Office to establish global standardization for Project Management and Resource Management.
Rafiqul Islam, Senior Director, Global Bioanalytical Services, Celerion, Inc.
Rafiqul Islam is the Senior Director of Bioanalytical Services at Celerion, Inc. In his current role he is be responsible for the scientific and operational leadership for both small and large molecule bioanalysis. He is also responsible for developing and executing a strategic plan to deliver scientific, operational and service excellence to Celerion clients. Previously, Rafiq held positions at EMD Millipore where he was the Scientific Director for Biopharma Services. He held similar positions at Covance and Huntingdon Life Sciences. He also held several positions of increasing responsibility with Curagen Corporation. He has 14 years of industry experience.
Di Jiang, Senior Project Management Consultant, Integrated Project Management Company, Inc.
Di Jiang has over 7 years of experience bringing disciplined on-site consulting leadership to organizations facing critical business and project decisions. Di has worked with numerous Pharmaceutical, Biotech, and Health Care organizations on complex, cross functional, high visibility projects. Di’s experiences have spanned the management spectrum, ranging from pre-clinical development to commercial launch and from project management leadership to portfolio management implementation. Notable client partners include Pfizer, Eli Lilly, Mallinckrodt, Shionogi, Shire, and the American Academy of Orthopedic Surgeons. Di holds Bachelor’s and Master’s degrees in Biomedical Engineering and Biology from Brown University, and is a certified Project Management Professional.
Elayne Ko, Manager, Strategy Group, Siemens Medical Solutions
Elayne Ko is a Manager in the Strategy Group of Siemens’ Health Services (HS) Business Unit focusing on portfolio management and business planning. Prior to Siemens, Elayne worked as a Manager at Deloitte Financial Advisory Services LLP to support client decision-making under risks, uncertainties and multiple objectives in the mining, financial services and pharmaceuticals. Before Deloitte, Elayne spent 7 years at Pfizer’s Portfolio and Decision Analysis (PDA) group where worked extensively on drug research and development investment decisions, long-term strategic planning, and disease area prioritization. Her project experiences spanned across a number of therapeutic areas including infectious diseases, neuroscience, urology, pain, oncology and cardiovascular. Elayne holds a BS in Management Sciences and MS in Decision Sciences from The London School of Economics.
William Korinek, Ph.D., Vice President, Worldwide R&D Business Operations, Pfizer
Dr. William Korinek is currently Vice President, Worldwide R&D Business Operations at Pfizer. He joined Pfizer in 2005 and has advanced through a number of strategic and operational positions driving short and long term R&D productivity improvements. Dr. Korinek managed the R&D Program Management Office (PMO) for the Pfizer-Wyeth integration, and led the PMO for Pfizer WRD’s 2011 “Engine for Sustainable Innovation” strategic restructuring involving the reduction of Pfizer’s overall R&D 2012 spend from $8.0-8.5B to $6.5-7.0B. As Head of WRD Business Operations, he is leading the integration of business operations, processes, and related systems across R&D to optimize project planning, resource management, financial forecasting, and portfolio delivery. Dr. Korinek previously worked as an Engagement Manager at the strategy consulting firm L.E.K. Consulting, where he worked with over 40 biotech and pharmaceutical companies on issues such as strategic planning, portfolio prioritization, and M&A due diligence. He earned his Ph.D. in Biochemistry from Harvard University’s Molecular and Cellular Biology Department, and has published in leading journals including Science.
Simone Kraemer, Ph.D., Associate Director, Reporting Capabilities, Bristol-Myers Squibb
John LaMattina, Senior Partner, PureTech Ventures
Dr. John L. LaMattina is the former Senior Vice President, Pfizer, Inc. and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007. Dr. LaMattina spent 30 years at Pfizer Inc having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation rheumatoid arthritis and AIDS. Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He is also a contributor to Forbes.com. Dr. LaMattina is a Senior Partner at PureTech Health. He serves on the Board of Directors of Ligand Pharmaceuticals, Ziarco Pharmaceuticals, Zafgen, and the Scientific Advisory Board of Trevena Pharmaceuticals. Dr. LaMattina also serves on the Board of Trustees of Boston College where he chairs the Academic Affairs Committee.
Sam Mathew, MBA, Portfolio Capacity Management Leader, Finance/PMO, Janssen Pharmaceuticals
Sam Mathew (MBA, LSS BB, CEM, PMP), is a Portfolio Capacity Management Leader at Janssen Pharmaceuticals. He has over 18 years’ experience in pharmaceutical, R&D and management consulting, with particular focus on executive decision support, insightful information and analysis, forecasting, visualization, analytics and modeling. He has led internal and management consulting initiatives and teams at Merck, Accenture, Pfizer, BMS, Amgen, PepsiCo and Apple Computers.
Maureen McNamara, Executive Director, Global Project Management, Merck Research Laboratories
Maureen is an Executive Director in Global Project Management at Merck Research Laboratories. She has over 25 years’ experience in drug development including leading product development teams, portfolio and pipeline prioritization efforts and developing and mentoring Project Managers in the art of drug development project management. Maureen’s portfolio expertise spans discovery through life cycle management. She has been involved in decision making at the therapeutic area level and across therapeutic areas at the project and study levels. At Merck she was instrumental in the Merck and Schering Plough merger and the rapid integration of the two portfolios. From that point she led the portfolio decision making within the Global Scientific Strategy organization which was responsible for deciding the Discovery and Early Development portfolio. More recently Maureen led the portfolio decision making in collaboration with finance, commercial and manufacturing for the Late stage portfolio as part of the company reorganization and refocusing of priorities. Maureen holds a BS in Chemistry from the College of St Elizabeth and an MBA from Seton Hall University.
Carlos Nunes, Director, Portfolio & Decision Analysis, Pfizer
Carlos reports into the Portfolio, Strategy & Commercial Operations function at Pfizer where he is responsible for the cross-business medicine development portfolio management office. Involved in this practice is the maintenance of valuation standards for internal clinical development programs and business development opportunities; the management of the repository of current and historical portfolio valuations; and enterprise support for portfolio investment analytics. Carlos has 16 years with Pfizer, with service spanning multiple roles across Research, Development and Commercial disciplines and specializations in Informatics, Business Intelligence, Project and Resource Management and more recently in Project Valuation and Portfolio Investment Decision Support.
Dave Penndorf, Executive Consultant, Planisware USA
Dave Penndorf heads the implementation & consulting services at Planisware US. In addition to overseeing all consulting services from the San Francisco office, he is a solution architect and an executive implementation consultant. For over 8 years, Dave has been helping life science organizations translate project and portfolio management business processes into practical solutions within Planisware software, overseeing all aspects of implementation from requirements gathering to system delivery and adoption. His time at Planisware has afforded him deep knowledge of industry best practices and front-line experience with what works and what doesn’t in portfolio and resource management. Dave holds a bachelor’s degree in Cognitive Science and Philosophy with a concentration in Computer Science from the University of Pennsylvania.
John Phillips, Director, Capital Efficiency, Business Valuation Consulting, Deloitte Transactions & Business Analytics
John Phillips is a Director in the Business Valuation Consulting practice of Deloitte Transactions & Business Analytics. John’s expertise is in assisting Life Science and Healthcare clients in strategic decision making pertaining to portfolio optimization, M&A/L&A, risk assessment and business valuation. John has worked nationally and internationally with clients in the pharmaceuticals, medical device, diagnostics, health care delivery, and health care insurance industries. Prior to joining Deloitte, John spent 28 years in the Life Sciences industry in management roles in R&D, Sales, New Product Development, and Strategic Marketing.
George Santangelo, Ph.D., Head, Office of Portfolio Analysis (OPA), Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), NIH
Dr. George Santangelo is the Director of the Office of Portfolio Analysis (OPA/DPCPSI/OD). George received a B.A. in Molecular Biology from the University of Pennsylvania and a Ph.D. in Genetics from Yale University. He did his postdoctoral work on two University of California campuses (Irvine and Santa Cruz), and from 2000 to 2009 was Professor of Biological Sciences at the University of Southern Mississippi. His NSF-and NIH-funded research has focused on glucose signaling and the role of nuclear organization in transcriptional regulation. His research output includes a 2005 paper in the Proceedings of the National Academy of Sciences that was designated a “Must Read” by the Faculty of 1000 and featured in The Scientist that same year in an article entitled “A Nuclear Model of Gene Regulation.”
Michael Shires, Vice President, Program and Portfolio Management, Baxter Healthcare
Mike Shires role within Baxter is Vice President of Program and Portfolio Management for Baxter's BioScience Business. Mike is responsible for the Project Management Function including Policies, Practices and Resourcing. Mike is a member of the BioScience Senior Management Team reporting to the BioScience President. Mike chairs the Baxter Project Management Council, which includes representatives from all Baxter businesses. Mike is directly responsible for the planning and execution of the New Product Development, Operations and Launch Pipeline of projects for the Baxter BioScience business. In the portfolio elements of his job – Mike is responsible for the Prioritization and Analytical Analysis of those projects. Prior to Baxter, Mike successfully developed and led the Project Management Offices for Divisions of Motorola and 3Com. He started his career in the Aerospace Industry with the US Government and Lockheed-Martin. His last assignment in this industry was as the Project Lead for the then largest international sale of military aircraft. Mike is married, with two children.
Richard Sonnenblick, Ph.D., CEO, Enrich Consulting
Richard Sonnenblick, the CEO of Enrich Consulting, has been with Enrich since its inception in 1998. The vision he brought to Enrich has been realized in the Enrich Analytics Platform. Prior to founding Enrich, he built a decision analysis consulting practice at Lumina Decision Systems, where he worked on integrated assessments of environmental legislation and R&D valuation models for high technology firms. Dr. Sonnenblick holds a Ph.D. and MS from Carnegie Mellon University in Engineering and Public Policy, and a BA in Physics from the University of California, Santa Cruz.
Tom Stone, Director, Strategy, Siemens Health Services
Tom Stone is a Director in Siemens Health Services Strategy group, with principal focus on Benchmarking activities. With Siemens for the past 23 years, Tom has applied his financial skills in a variety cross functional settings. Primary responsibilities have included a broad range of topics including financial analysis and controlling, strategic / business planning, project management, benchmarking, competitive analysis, compliance and transfer pricing. Tom has executed these responsibilities in both US and International departments. Prior to Tom’s current role in Strategy, his most recent responsibilities included Financial Officer for Health Services International, a $30M US-based portfolio for emerging markets, and earlier served as Director of the Strategic Projects Office which, in conjunction with the Boston Consulting Group, directed the planning and execution of major strategic initiatives targeting specific productivity gains and over 5-year strategic plan.
Bennet Vallet, Director, Product Development, Siemens
Bennet Vallet has been at Siemens Health Services for over 20 years and is a Director of Product Development where he leads the Agile Center of Competency. Previous to that Bennet held multiple leadership roles within the company’s Product Lifecycle Management (PLM) organization where he has been involved continuously in the development of large scale healthcare information systems. Bennet has been involved in leading agile transformations since 2005, the year the company adopted Scrum/XP. In addition to his current management responsibilities, Bennet is the agile strategist on the company’s product development excellence team, chartered to drive key improvement initiatives with respect to people, process and infrastructure. In this capacity Bennet is currently driving the company’s adoption of key change initiatives including the rollout of Kanban and the training and development of Agile coaches.
Phil Wolf, Senior Vice President, Enterprise and On Demand Products, PDWare
Daniel Zweidler, Ph.D., Senior Fellow, Mack Institute for Innovation Management, The Wharton School, UPenn; President, DZA, Inc.
Dr. Daniel Zweidler is a leading strategy and portfolio optimization expert, who is also known as a futurist and a champion of open innovation and co-creation. Dr. Zweidler helps energy and health care organizations make better investment decisions by blending scenario planning, strategic thinking and portfolio option planning techniques. He has an exceptional ability to bridge cross-cultural, multi-national differences in collaborative team environments as a result of a career that spans 20+ countries across six continents and his multi-lingual fluency.
Dr. Zweidler is currently a Senior Fellow at the Mack Center for Technological Innovation and is President of Daniel Zweidler & Associates, a boutique management-consulting firm. Prior to that, Dr. Zweidler was SVP at Merck & Head of Portfolio Management/Global Scientific Strategy. He previously had been at Royal Dutch Shell, holding diverse roles such as Head of Global Exploration Planning & Portfolio, Exploration Planning and Portfolio Manager, and Senior Exploration Consultant, after starting with the firm as an Exploration Geologist in The Hague, Netherlands. Dr. Zweidler studied at Université de Neuchâtel in Switzerland, where he received both his master's and his doctorate in geology. He lectured extensively on the subject of strategic thinking and portfolio option planning as part of Shell’s executive education program at the Judge Business School, University of Cambridge. Dr. Zweidler has presented numerous papers in both academic and industry settings, and co-authored the foundational paper on Probability Management in OR/MS Today. He is a member of the Long Now Foundation, the Institute for Operations Research and the Management Sciences, the American Association of Petroleum Geologists and the Swiss Geological Society. He also served as president of the Swiss American Society of New Orleans between 1997 and 2000. Dr. Zweidler is committed to identifying socially responsible strategies that help organizations maximize value, increase capital efficiency, and reduce enterprise risk while optimizing investments in their Innovation, R&D, and Exploration portfolios.